Santacruzamate A has shown potential in cancer research due to its ability to inhibit histone deacetylases (HDACs), which play a critical role in gene expression and cell cycle regulation. By targeting HDACs, it may help in the reactivation of tumor suppressor genes, making it a promising candidate for anticancer therapy. Additionally, its selective inhibition properties could lead to the development of more targeted treatments with fewer side effects compared to traditional chemotherapy. Research is ongoing to explore its efficacy and safety in preclinical models, with the aim of advancing it toward clinical trials for various cancers.